24 febrero 2015
Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/O6BDmbf0tJc/150224091732.htm
